-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
A few days ago, the CDE official website showed that Shandong Buchang Pharmaceutical's olmesartan medoxomil tablets for generic 4 types of applications were accepted by CDE
.
According to data from Menet.
com, the combined sales of Olmesartan medoxomil tablets in China's public medical institution terminals and China's urban physical pharmacy terminals will exceed 700 million yuan in 2020, of which, China's urban physical pharmacy terminals will increase by more than 20%
.
.
According to data from Menet.
com, the combined sales of Olmesartan medoxomil tablets in China's public medical institution terminals and China's urban physical pharmacy terminals will exceed 700 million yuan in 2020, of which, China's urban physical pharmacy terminals will increase by more than 20%
.
Olmesartan medoxomil is a new generation of angiotensin Ⅱ receptor inhibitors, which has the characteristics of long acting time, good antihypertensive effect, and being taken orally without being affected by food
.
The original manufacturer of the product was Daiichi Sankyo, Japan.
In 2006, the olmesartan medoxomil tablets produced by Daiichi Sankyo Pharmaceutical (Shanghai) were launched in China
.
.
The original manufacturer of the product was Daiichi Sankyo, Japan.
In 2006, the olmesartan medoxomil tablets produced by Daiichi Sankyo Pharmaceutical (Shanghai) were launched in China
.
Sales of olmesartan medoxomil tablets in physical pharmacies in Chinese cities in recent years (unit: 100 million yuan)
Source: Mi Nei.
com, China's urban physical pharmacy terminal competition pattern
com, China's urban physical pharmacy terminal competition pattern
Meinenet data shows that in 2020, the total sales of olmesartan medoxomil tablets in China's urban public hospitals , county-level public hospitals, urban community centers and township health centers (Chinese public medical institutions) terminals and Chinese urban physical pharmacies terminals exceed 700 million.
Among them, the terminal growth rate of public medical institutions in China has declined, while the growth rate of physical pharmacies in cities in China has exceeded 20%
.
Among them, the terminal growth rate of public medical institutions in China has declined, while the growth rate of physical pharmacies in cities in China has exceeded 20%
.
Source: Meinenet MED2.
0 Chinese Drug Evaluation Database
0 Chinese Drug Evaluation Database
There are 11 manufacturers of Olmesartan medoxomil tablets, and Daiichi Sankyo has the largest market share
.
In terms of consistency evaluation, 8 companies have been reviewed.
Nanjing Chia Tai Tianqing Pharmaceutical and Beijing Fuyuan Pharmaceutical have been approved for supplementary applications; 6 companies including Guangdong Dongyang Sunshine Pharmaceutical, Qilu Pharmaceutical, and Chengdu Beite Pharmaceutical have used generic 4 categories The application for production is approved, and it is deemed as over-evaluated
.
.
In terms of consistency evaluation, 8 companies have been reviewed.
Nanjing Chia Tai Tianqing Pharmaceutical and Beijing Fuyuan Pharmaceutical have been approved for supplementary applications; 6 companies including Guangdong Dongyang Sunshine Pharmaceutical, Qilu Pharmaceutical, and Chengdu Beite Pharmaceutical have used generic 4 categories The application for production is approved, and it is deemed as over-evaluated
.
Currently, the products are on the Yangtze River Pharmaceutical Group, Shanghai Haini medicine, Qingdao Yellow Sea pharmaceutical, Zhejiang Connaught in medicine and other five companies to submit the listing application imitation in four categories in the review and approval
.
.
Source: CDE official website, Minet.
com database
com database
Note: China's urban entity pharmacy terminal competition pattern database is an enlarged version of the urban entity pharmacy database that covers 293 prefectures and cities across the country (excluding county and rural entity pharmacies), and continuously monitors all categories
.
The above sales are calculated based on the average retail price of the product at the terminal
.
.
The above sales are calculated based on the average retail price of the product at the terminal
.
A few days ago, the CDE official website showed that Shandong Buchang Pharmaceutical's olmesartan medoxomil tablets for generic 4 types of applications were accepted by CDE
.
According to data from Menet.
com, the combined sales of Olmesartan medoxomil tablets in China's public medical institution terminals and China's urban physical pharmacy terminals will exceed 700 million yuan in 2020, of which, China's urban physical pharmacy terminals will increase by more than 20%
.
.
According to data from Menet.
com, the combined sales of Olmesartan medoxomil tablets in China's public medical institution terminals and China's urban physical pharmacy terminals will exceed 700 million yuan in 2020, of which, China's urban physical pharmacy terminals will increase by more than 20%
.
Olmesartan medoxomil is a new generation of angiotensin Ⅱ receptor inhibitors, which has the characteristics of long acting time, good antihypertensive effect, and being taken orally without being affected by food
.
The original manufacturer of the product was Daiichi Sankyo, Japan.
In 2006, the olmesartan medoxomil tablets produced by Daiichi Sankyo Pharmaceutical (Shanghai) were launched in China
.
.
The original manufacturer of the product was Daiichi Sankyo, Japan.
In 2006, the olmesartan medoxomil tablets produced by Daiichi Sankyo Pharmaceutical (Shanghai) were launched in China
.
Sales of olmesartan medoxomil tablets in physical pharmacies in Chinese cities in recent years (unit: 100 million yuan)
Source: Mi Nei.
com, China's urban physical pharmacy terminal competition pattern
com, China's urban physical pharmacy terminal competition pattern
Meinenet data shows that in 2020, the total sales of olmesartan medoxomil tablets in China's urban public hospitals , county-level public hospitals, urban community centers and township health centers (Chinese public medical institutions) terminals and Chinese urban physical pharmacies terminals exceed 700 million.
Among them, the terminal growth rate of public medical institutions in China has declined, while the growth rate of physical pharmacies in cities in China has exceeded 20%
.
Among them, the terminal growth rate of public medical institutions in China has declined, while the growth rate of physical pharmacies in cities in China has exceeded 20%
.
Source: Meinenet MED2.
0 Chinese Drug Evaluation Database
0 Chinese Drug Evaluation Database
There are 11 manufacturers of Olmesartan medoxomil tablets, and Daiichi Sankyo has the largest market share
.
In terms of consistency evaluation, 8 companies have been reviewed.
Nanjing Chia Tai Tianqing Pharmaceutical and Beijing Fuyuan Pharmaceutical have been approved for supplementary applications; 6 companies including Guangdong Dongyang Sunshine Pharmaceutical, Qilu Pharmaceutical, and Chengdu Beite Pharmaceutical have used generic 4 categories The application for production is approved, and it is deemed as over-evaluated
.
.
In terms of consistency evaluation, 8 companies have been reviewed.
Nanjing Chia Tai Tianqing Pharmaceutical and Beijing Fuyuan Pharmaceutical have been approved for supplementary applications; 6 companies including Guangdong Dongyang Sunshine Pharmaceutical, Qilu Pharmaceutical, and Chengdu Beite Pharmaceutical have used generic 4 categories The application for production is approved, and it is deemed as over-evaluated
.
Currently, the products are on the Yangtze River Pharmaceutical Group, Shanghai Haini medicine, Qingdao Yellow Sea pharmaceutical, Zhejiang Connaught in medicine and other five companies to submit the listing application imitation in four categories in the review and approval
.
.
Source: CDE official website, Minet.
com database
com database
Note: China's urban entity pharmacy terminal competition pattern database is an enlarged version of the urban entity pharmacy database that covers 293 prefectures and cities across the country (excluding county and rural entity pharmacies), and continuously monitors all categories
.
The above sales are calculated based on the average retail price of the product at the terminal
.
.
The above sales are calculated based on the average retail price of the product at the terminal
.
A few days ago, the CDE official website showed that Shandong Buchang Pharmaceutical's olmesartan medoxomil tablets for generic 4 types of applications were accepted by CDE
.
According to data from Menet.
com, the combined sales of Olmesartan medoxomil tablets in China's public medical institution terminals and China's urban physical pharmacy terminals will exceed 700 million yuan in 2020, of which, China's urban physical pharmacy terminals will increase by more than 20%
.
.
According to data from Menet.
com, the combined sales of Olmesartan medoxomil tablets in China's public medical institution terminals and China's urban physical pharmacy terminals will exceed 700 million yuan in 2020, of which, China's urban physical pharmacy terminals will increase by more than 20%
.
Olmesartan medoxomil is a new generation of angiotensin Ⅱ receptor inhibitors, which has the characteristics of long acting time, good antihypertensive effect, and being taken orally without being affected by food
.
The original manufacturer of the product was Daiichi Sankyo, Japan.
In 2006, the olmesartan medoxomil tablets produced by Daiichi Sankyo Pharmaceutical (Shanghai) were launched in China
.
.
The original manufacturer of the product was Daiichi Sankyo, Japan.
In 2006, the olmesartan medoxomil tablets produced by Daiichi Sankyo Pharmaceutical (Shanghai) were launched in China
.
Sales of olmesartan medoxomil tablets in physical pharmacies in Chinese cities in recent years (unit: 100 million yuan)
Source: Mi Nei.
com, China's urban physical pharmacy terminal competition pattern
com, China's urban physical pharmacy terminal competition pattern
Meinenet data shows that in 2020, the total sales of olmesartan medoxomil tablets in China's urban public hospitals , county-level public hospitals, urban community centers and township health centers (Chinese public medical institutions) terminals and Chinese urban physical pharmacies terminals exceed 700 million.
Among them, the terminal growth rate of public medical institutions in China has declined, while the growth rate of physical pharmacies in cities in China has exceeded 20%
.
Hospital hospital hospital pharmacy pharmacy pharmacyAmong them, the terminal growth rate of public medical institutions in China has declined, while the growth rate of physical pharmacies in cities in China has exceeded 20%
.
Source: Meinenet MED2.
0 Chinese Drug Evaluation Database
0 Chinese Drug Evaluation Database
There are 11 manufacturers of Olmesartan medoxomil tablets, and Daiichi Sankyo has the largest market share
.
In terms of consistency evaluation, 8 companies have been reviewed.
Nanjing Chia Tai Tianqing Pharmaceutical and Beijing Fuyuan Pharmaceutical have been approved for supplementary applications; 6 companies including Guangdong Dongyang Sunshine Pharmaceutical, Qilu Pharmaceutical, and Chengdu Beite Pharmaceutical have used generic 4 categories The application for production is approved, and it is deemed as over-evaluated
.
Medicine Medicine Medicine.
In terms of consistency evaluation, 8 companies have been reviewed.
Nanjing Chia Tai Tianqing Pharmaceutical and Beijing Fuyuan Pharmaceutical have been approved for supplementary applications; 6 companies including Guangdong Dongyang Sunshine Pharmaceutical, Qilu Pharmaceutical, and Chengdu Beite Pharmaceutical have used generic 4 categories The application for production is approved, and it is deemed as over-evaluated
.
Currently, the products are on the Yangtze River Pharmaceutical Group, Shanghai Haini medicine, Qingdao Yellow Sea pharmaceutical, Zhejiang Connaught in medicine and other five companies to submit the listing application imitation in four categories in the review and approval
.
Enterprise business enterprise.
Source: CDE official website, Minet.
com database
com database
Note: China's urban entity pharmacy terminal competition pattern database is an enlarged version of the urban entity pharmacy database that covers 293 prefectures and cities across the country (excluding county and rural entity pharmacies), and continuously monitors all categories
.
The above sales are calculated based on the average retail price of the product at the terminal
.
.
The above sales are calculated based on the average retail price of the product at the terminal
.
